Health

Porton Advanced Announces a Strategic Partnership with BioMap, with AI Models Facilitating AAV Gene Therapy Development

SUZHOU, China, Nov. 8, 2023 /PRNewswire/ -- On November 8, 2023, Porton Advanced announced the establishment of a strategic partnership with BioMap. BioMap will leverage Porton Advanced's unique Adeno-Associated Virus (AAV) vector technology platform and research data to develop AAV assembly effi...

2023-11-08 22:31 2181

Complete Genomics' DNBSEQ-T20x2RS* Named "Next Generation Sequencing Solution of the Year" by 2023 BioTech Breakthrough Awards Program

Third Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry SAN JOSE, Calif., Nov. 8, 2023 /PRNewswire/ -- Complete Genomics,  a pioneering genomic sequencing company, today announced it is the recipient of the 2023 "Nex...

2023-11-08 22:00 2075

China Jo-Jo Drugstores Announces Celebration of its 20th Anniversary

HANGZHOU, China, Nov. 8, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that its 2...

2023-11-08 21:30 3827

Nuvilab Earns Top Honors in Korea's AI Startup 100, Transforming Food Industry with AI Food Scanner 3.0

SEOUL, South Korea, Nov. 8, 2023 /PRNewswire/ -- Nuvilab, the South Korean AI pioneer in food digitalization locked in its spot for Korea AI Startup 100. The Korea AI Startup 100 recognizes aspiring startups inSouth Korea to foster the healthy growth of the next-generation AI industry ecosystem. ...

2023-11-08 14:53 1780

WuXi Biologics Receives AAA MSCI ESG Rating

SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings, the highest rating for compan...

2023-11-08 08:30 1548

Rootique DUO launches on Indiegogo, revolutionizing hair loss treatment with a 15s mess-free process

HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Rootique, a startup that leverages technology to optimize the performance of hair loss solutions, announced today the launch of its pioneering product Rootique DUO, designed to simplify the application of topical hair loss treatments to boost the chance of ...

2023-11-08 00:00 1430

Nuevocor presents pre-clinical data at ESGCT and AHA meetings

SINGAPORE, Nov. 7, 2023 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnologycompany focused on developing cardiac genetic medicines through a unique platform to understand the mechanobiological causes of disease, announced today a pair of presentations at two major meetings, the European ...

2023-11-07 22:00 1748

MAJOR FITNESS opens pre-orders on its less space, more exercises foldable power rack, the Lightning F35

ATLANTA, Ga., Nov. 7, 2023 /PRNewswire/ -- Optimizing gym equipment so people can train at home on a budget, even ifthey live in an apartment with limited space, is in reach more than ever now with the launch of the newall-in-one Lightning F35 from MAJOR FITNESS.

2023-11-07 22:00 1697

Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial

SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have no...

2023-11-07 21:58 1369

Kexing Biopharm Attended CPHI Worldwide 2023

SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ -- Recently, CPHI Worldwide 2023 was successfully held inBarcelona, Spain. Kexing Biopharm exhibited more than ten kinds of high-quality medical products in the fields of tumor, autoimmune, anti-virus, etc., including Infliximab, Adalimumab, Bevacizumab,...

2023-11-07 20:09 1526

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (开坦尼®) in combination with capecitabine plus...

2023-11-07 20:00 1940

First Mover of Global Trade Index Based On Biome Molecule, Kwanyoung Park of AndKwan Natural Science

* Creating world-class innovation by redefining how international standards are established with eco-friendly bio materials and a system. * Patent registration for one-stop system from procurement of raw materials and golden time orders from all over the world to search for optimal routes for ...

2023-11-07 15:47 1831

BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate

SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate (ADC) targeting LIV-1 for the treatment of advanced malign...

2023-11-07 14:14 1404

87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting

SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib(ABSK021)were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held inIreland from...

2023-11-07 12:31 1511

AIRS Medical inks partnership agreement with FONAR Corporation, leveraging the experience of the pioneering company in MRI... Success cases to be presented at RSNA 2023

SEOUL, South Korea, Nov. 6, 2023 /PRNewswire/ -- AIRS Medical, the leading AI-powered healthcare solution provider, recently announced a strategic partnership with FONAR Corporation (NASDAQ:FONR), the pioneer company in the MRI industry, to accelerate and develop business inNorth America. AIRS M...

2023-11-07 00:00 1823

Lerna Bio unveils its first-in-class solution to combat liver failure

SINGAPORE, CAMBRIDGE, Mass. and SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Lerna Biopharma Pte. Ltd (Lerna Bio) proudly announces the unveiling of its pioneering liver regeneration drug candidate, LR1, at The Liver Meeting inBoston organized by American Association for the Study of Liver Diseases (AA...

2023-11-06 22:00 1486

First in the U.S! Palliative Care VR Educational Material by Jolly Good and Emergency Medicine Specialists

Jolly Good to hold VR Seminar at GSA 2023, Gerontological Society of America! TOKYO, Nov. 6, 2023 /PRNewswire/ -- Jolly Good US Inc. (Brookline, Massachusetts, USA CEO: Kensuke Joji), a developer of medical VR, is pleased to announce that it has developed the first "Palliative Care Communication ...

2023-11-06 21:00 1477

Lunit to Present Seven AI-Powered Radiology Studies at RSNA 2023

* Two oral presentations and five ePosters accepted by the RSNA: presenting AI advancements for chest radiograph reporting efficiency and breast cancer risk assessment SEOUL, South Korea, Nov. 6, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer ...

2023-11-06 21:00 1467

I-Mab Announces Participation at Jefferies and Piper Conferences in November

ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies...

2023-11-06 21:00 1435

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications

Bispecific Antibody Candidate PM8002 demonstrated encouraging data at this year's ASCO Annual Meeting (abstract #2536 & #e13091) and ESMO Congress (abstract #1992P) BioNTech will hold exclusive licenses to develop and commercialize PM8002 globally excluding Greater China   ZHUHAI, China, Nov. 6...

2023-11-06 20:00 2210
1 ... 63646566676869 ... 280